Fig. 7: Tebentafusp treatment induces upregulation of anti-tumoral macrophage gene signatures in patients with mUM. | Nature Communications

Fig. 7: Tebentafusp treatment induces upregulation of anti-tumoral macrophage gene signatures in patients with mUM.

From: Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer

Fig. 7

a Schematic illustration of tumor sample processing for bulk RNA-seq. b Gene set enrichment analysis using M1- and M2-associated gene list in bulk RNA-seq of patients 16 days on tebentafusp treatment (n = 35 patients, two-sided adjusted p values are shown using ReactomePA package). c Selected M1-associated and M2-associated gene expression pre-treatment and 16 days on-tebentafusp treatment in patients with mUM (n = 35 patients, paired Wilcoxon test, two-sided p values < 0.05 are shown). Abbreviations: M1 = M1 macrophages, M2 = M2 macrophages, FC = Fold-change, TPM = Transcripts Per Million, NES = Normalized Enrichment Score, ns = not significant.

Back to article page